Form 4: Rhythm Pharmaceuticals Director Exercises Stock Options
SEC Form 4 Filing
Director David W.J. McGirr exercised options to acquire 3,000 shares of Rhythm Pharmaceuticals common stock on June 21, 2024.
Summary
- David W.J. McGirr, a director of Rhythm Pharmaceuticals, exercised options to acquire 3,000 shares of common stock on June 21, 2024.
- The transaction involved the exercise of restricted stock units, each representing a contingent right to receive one share of Rhythm Pharmaceuticals common stock.
- The restricted stock units fully vested on June 21, 2024, and have no expiration date.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock option exercises, and it doesn't inherently indicate positive or negative sentiment. It's a neutral event.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. This provides transparency to the market.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the increase in the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 06/21/2024 | Date of transaction: exercise of stock options and vesting of restricted stock units. |
| 06/25/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.